FI51587C - Förfarande för framställning av sulfamyl-m-aminobensoesyror med terape utisk verkan. - Google Patents

Förfarande för framställning av sulfamyl-m-aminobensoesyror med terape utisk verkan.

Info

Publication number
FI51587C
FI51587C FI693661A FI366169A FI51587C FI 51587 C FI51587 C FI 51587C FI 693661 A FI693661 A FI 693661A FI 366169 A FI366169 A FI 366169A FI 51587 C FI51587 C FI 51587C
Authority
FI
Finland
Prior art keywords
sulfamyl
preparation
therapeutic action
aminobenzoic acids
aminobenzoic
Prior art date
Application number
FI693661A
Other languages
English (en)
Finnish (fi)
Other versions
FI51587B (sv
Inventor
Peter Werner Feit
Original Assignee
Leo Pharm Prod Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB38038/69A external-priority patent/GB1249490A/en
Application filed by Leo Pharm Prod Ltd filed Critical Leo Pharm Prod Ltd
Publication of FI51587B publication Critical patent/FI51587B/fi
Application granted granted Critical
Publication of FI51587C publication Critical patent/FI51587C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
FI693661A 1968-12-24 1969-12-17 Förfarande för framställning av sulfamyl-m-aminobensoesyror med terape utisk verkan. FI51587C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB38038/69A GB1249490A (en) 1968-12-24 1968-12-24 New sulphamyl-benzoic acid derivatives
GB3089869 1969-06-18
US84593969A 1969-07-24 1969-07-24
GB3803869 1969-07-29

Publications (2)

Publication Number Publication Date
FI51587B FI51587B (sv) 1976-11-01
FI51587C true FI51587C (sv) 1977-02-10

Family

ID=27448796

Family Applications (1)

Application Number Title Priority Date Filing Date
FI693661A FI51587C (sv) 1968-12-24 1969-12-17 Förfarande för framställning av sulfamyl-m-aminobensoesyror med terape utisk verkan.

Country Status (14)

Country Link
JP (2) JPS5420483B1 (sv)
BE (1) BE743744A (sv)
CH (1) CH532559A (sv)
DE (2) DE1964503A1 (sv)
DK (1) DK134548B (sv)
FI (1) FI51587C (sv)
FR (1) FR2027043B1 (sv)
IE (1) IE33874B1 (sv)
IS (1) IS985B6 (sv)
IT (1) IT1143801B (sv)
NL (1) NL154727B (sv)
NO (1) NO132234C (sv)
SE (1) SE380013B (sv)
YU (1) YU34983B (sv)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647873A (en) * 1970-02-03 1972-03-07 Merck & Co Inc Nuclear sulfonyl substituted n-acyl-benzenesulfonamides
AR206507A1 (es) * 1972-10-13 1976-07-30 Ciba Geigy Ag Procedimiento para la obtencion de nuevos 4-eteres de acidos 3-amino-5-sulfamoilbenzoicos
DE2419970C3 (de) * 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
CA1135705A (en) * 1978-07-20 1982-11-16 Jens-Uwe Bliesener N-arylsulfonylpyrroles, their preparation, and therapeutic agents containing these compounds
DE3941703C2 (de) * 1989-12-18 2002-11-07 Sanol Arznei Schwarz Gmbh Bumetanid enthaltende pharmazeutische Zubereitung

Also Published As

Publication number Publication date
DE1964504A1 (de) 1970-07-09
FI51587B (sv) 1976-11-01
IS1894A7 (is) 1971-06-25
JPS5024299B1 (sv) 1975-08-14
SE380013B (sv) 1975-10-27
NO132234C (sv) 1975-10-08
JPS5420483B1 (sv) 1979-07-23
BE743744A (sv) 1970-06-24
CH532559A (de) 1973-01-15
IE33874L (en) 1970-06-24
DE1964504C3 (de) 1978-03-02
DE1964504B2 (de) 1977-07-07
NO132234B (sv) 1975-06-30
NL154727B (nl) 1977-10-17
DK134548C (sv) 1977-05-02
NL6919391A (sv) 1970-06-26
YU319069A (en) 1979-12-31
IT1143801B (it) 1986-10-22
FR2027043B1 (sv) 1978-08-18
YU34983B (en) 1980-06-30
DK134548B (da) 1976-11-29
IE33874B1 (en) 1974-11-27
FR2027043A1 (sv) 1970-09-25
IS985B6 (is) 1978-02-22
DE1964503A1 (de) 1970-07-09

Similar Documents

Publication Publication Date Title
FI49035C (sv) Förfarande för framställning av terapeutiskt användbart 2-brom-alfa-er gokryptin.
FI50059C (sv) Förfarande för framställning av tablettliknande doseringsenheter med f ördröjd verkan.
FI48590C (sv) Förfarande för framställning av terapeutiskt användbara azaspiroalkand ionföreningar.
FI51347C (sv) Förfarande för framställning av 1-substituerade-3- och -4-arylpiperidi ner.
FI48062C (sv) Förfarande för framställning av xylitol
FI50334C (sv) Förfarande för framställning av 1-hydroxy-2-pyridoner.
FI50409C (sv) Förfarande för framställning av pyridin-karboxylsyror
FI49512C (sv) Förfarande för framställning av nya terapeutiskt aktiva s-triazinyl-pi perazinderivat.
FI50410C (sv) Förfarande för framställning av inflammationshämmande substituerade am inopyridiner
FI48463C (sv) Förfarande för framställning av bensensulfonylkarbamider med blodsocke rsänkande verkan.
FI51587C (sv) Förfarande för framställning av sulfamyl-m-aminobensoesyror med terape utisk verkan.
FI47575C (sv) Analogiförfarande för framställning av evomonosid-derivat.
FI49407C (sv) Förfarande för framställning av kinolinkarbonsyraestrar med coccidiost atisk verkan.
FI45963C (sv) Förfarande för framställning av bentsensulfonylkarbamider med blodsock ersänkande verkan.
FI50407C (sv) Förfarande för framställning av triklormonosilaner
FI45964C (sv) Förfarande för framställning av bensensulfonylkarbamider med blodsocke rsänkande verkan.
FI46727C (sv) Förfarande för framställning av pyridazolderivat.
FI47578C (sv) Förfarande för framställning av 2,4,7-triamino-6-fenyl-pteridiner med hjärtats kranskärl utvidgande verkan.
FI52577C (sv) Förfarande för framställning av terapeutiskt användbara fenazinderivat .
FI47189C (sv) Förfarande för framställning av terapeutiskt aktiva d-lyserginsyra-N-f enylpiperazider.
FI47350C (sv) Förfarande för framställning av 17alfa-propadienyl-steroider.
FI47358C (sv) Förfarande för framställning av terapeutiskt användbart 4&#39;-demetyl-epi podofyllotoxin-beta-D-glukosid.
FI51814C (sv) Förfarande för framställning av alfa-karboxibensylpenicillin.
FI46155C (sv) Förfarande för framställning av bensensulfonylkarbamider med blodsocke rsänkande verkan.
FI46722C (sv) Förfarande för framställining av 1alpha-hydroxi-18-metyl-5alpha-H-andr ostanderivat.